Marshall Wace’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-380,919
| Closed | -$18.7M | – | 3409 |
|
|
2025
Q4 | $18.7M | Buy |
380,919
+317,030
| +496% | +$14.8M | 0.02% | 654 |
|
|
2025
Q3 | $2.76M | Buy |
+63,889
| New | +$2.5M | ﹤0.01% | 1465 |
|
|
2024
Q4 | – | Sell |
-283,376
| Closed | -$11.6M | – | 2749 |
|
|
2024
Q3 | $11.6M | Buy |
+283,376
| New | +$11.6M | 0.01% | 712 |
|
|
2023
Q4 | – | Sell |
-330,976
| Closed | -$12M | – | 2337 |
|
|
2023
Q3 | $12M | Buy |
330,976
+95,882
| +41% | +$3.4M | 0.02% | 590 |
|
|
2023
Q2 | $8.38M | Sell |
235,094
-1,574,261
| -87% | -$56.5M | 0.02% | 816 |
|
|
2023
Q1 | $64.4M | Buy |
1,809,355
+1,574,304
| +670% | +$55.1M | 0.14% | 162 |
|
|
2022
Q4 | $8.26M | Buy |
235,051
+121,550
| +107% | +$4.05M | 0.02% | 907 |
|
|
2022
Q3 | $3.34M | Sell |
113,501
-229,989
| -67% | -$8.72M | 0.01% | 1677 |
|
|
2022
Q2 | $18.7M | Sell |
343,490
-1,439,310
| -81% | -$79.5M | 0.04% | 493 |
|
|
2022
Q1 | $97.1M | Buy |
+1,782,800
| New | +$96.8M | 0.18% | 110 |
|
|
2021
Q1 | – | Sell |
-44,954
| Closed | -$2.07M | – | 2620 |
|
|
2020
Q4 | $2.07M | Sell |
44,954
-311,888
| -87% | -$14.3M | 0.01% | 933 |
|
|
2020
Q3 | $16.8M | Buy |
356,842
+317,125
| +798% | +$15.9M | 0.11% | 191 |
|
|
2020
Q2 | $2.02M | Buy |
+39,717
| New | +$2.04M | 0.01% | 788 |
|
|
2019
Q4 | – | Sell |
-70,888
| Closed | -$3.78M | – | 1844 |
|
|
2019
Q3 | $3.78M | Buy |
+70,888
| New | +$3.65M | 0.03% | 581 |
|
|
2019
Q2 | – | Sell |
-899
| Closed | -$47K | – | 1535 |
|
|
2019
Q1 | $47K | Hold |
899
| – | – | ﹤0.01% | 1542 |
|
|
2018
Q4 | $43K | Buy |
+899
| New | +$44.3K | ﹤0.01% | 1464 |
|
|
2018
Q1 | – | Sell |
-5,099
| Closed | -$226K | – | 596 |
|
|
2017
Q4 | $226K | Sell |
5,099
-29,239
| -85% | -$1.35M | 0.01% | 372 |
|
|
2017
Q3 | $1.76M | Buy |
34,338
+19,731
| +135% | +$1M | 0.08% | 174 |
|
|
2017
Q2 | $785K | Buy |
+14,607
| New | +$779K | 0.03% | 206 |
|
|
2017
Q1 | – | Sell |
-841,191
| Closed | -$40.5M | – | 477 |
|
|
2016
Q4 | $40.5M | Buy |
841,191
+213,704
| +34% | +$10.6M | 0.27% | 101 |
|
|
2016
Q3 | $33.8M | Buy |
+627,487
| New | +$34.4M | 0.24% | 101 |
|
|
2015
Q4 | – | Sell |
-56,867
| Closed | -$2.73M | – | 1029 |
|
|
2015
Q3 | $2.73M | Buy |
+56,867
| New | +$2.96M | 0.03% | 393 |
|
Other funds holding GSK
JEST
Marshall Wace's GSK Position: Q1 2026 in Review
Marshall Wace sold out of GSK (GSK) in Q1 2026, closing a stake of 380,919 shares — an estimated $18.7M sold.
Marshall Wace first reported a position in GSK in Q3 2015 and held it in 22 quarters. The position peaked at $97.1M in Q1 2022. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Marshall Wace reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
- Marshall Wace sold 380,919 GSK shares in Q1 2026, an estimated $18.7M.
- Marshall Wace first reported a position in GSK in Q3 2015 and held it in 22 quarters.
- Marshall Wace's GSK position peaked at $97.1M in Q1 2022.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.